HomeCompareENMHF vs JNJ

ENMHF vs JNJ: Dividend Comparison 2026

ENMHF yields 5000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENMHF wins by $62217131802825.32M in total portfolio value
10 years
ENMHF
ENMHF
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full ENMHF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ENMHF vs JNJ

📍 ENMHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENMHFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENMHF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENMHF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENMHF
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ENMHF beats the other by $50,882,683,244,271,480,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENMHF + JNJ for your $10,000?

ENMHF: 50%JNJ: 50%
100% JNJ50/50100% ENMHF
Portfolio after 10yr
$31108565901412.69M
Annual income
$29,930,990,143,689,110,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ENMHF
No analyst data
Altman Z
29.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENMHF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENMHFJNJ
Forward yield5000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$62217131802825.35M$30.3K
Annual income after 10y$59,861,980,287,378,210,000.00$4,689.40
Total dividends collected$62057786341622.61M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ENMHF vs JNJ ($10,000, DRIP)

YearENMHF PortfolioENMHF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$510,700$500,000.00$10,592$272.30+$500.1KENMHF
2$24,410,935$23,864,485.98$11,289$357.73+$24.40MENMHF
3$1,092,192,501$1,066,072,800.30$12,123$472.89+$1092.18MENMHF
4$45,746,366,951$44,577,720,975.17$13,141$629.86+$45746.35MENMHF
5$1,793,932,828,410$1,744,984,215,772.56$14,408$846.81+$1793932.81MENMHF
6$65,871,973,805,320$63,952,465,678,921.49$16,021$1,151.60+$65871973.79MENMHF
7$2,265,146,887,602,700$2,194,663,875,631,007.20$18,122$1,588.22+$2265146887.58MENMHF
8$72,954,689,148,998,180$70,530,981,979,263,280.00$20,930$2,228.20+$72954689148.98MENMHF
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$24,792$3,191.91+$2201076182660.86MENMHF
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$30,274$4,689.40+$62217131802825.32MENMHF

ENMHF vs JNJ: Complete Analysis 2026

ENMHFStock

ENM Holdings Limited, an investment holding company, engages in the retail of fashion wear and accessories. It operates through three segments: Retail of Fashion Wear and Accessories; Resort and Recreational Club Operations; and Investments. The company operates a chain of multi-label stores, as well as mono-brand boutiques under The Swank brand in Hong Kong and China; and Hilltop Country Club that provides conferences, dining, lodging, recreational, and outdoor activities for its members in Hong Kong, as well as offers menswear fashion products under the Cesare di Pino brand name. It also holds and trades in investments for short term and long term investment returns. The company was formerly known as e-New Media Company Limited and changed its name to ENM Holdings Limited in June 2005. ENM Holdings Limited was incorporated in 1966 and is based in Tsuen Wan, Hong Kong.

Full ENMHF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ENMHF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENMHF vs SCHDENMHF vs JEPIENMHF vs OENMHF vs KOENMHF vs MAINENMHF vs ABBVENMHF vs MRKENMHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.